Dr Fox is a paid advisor to Sanofi for the HERCULES study. Erik Wallström, MD, PhD, global head of neurology development, said: “By targeting disability progression mechanisms behind the blood-brain ...

Mahavir Jayanti celebrates the birth of Lord Mahavir, the 24th Tirthankara of Jainism, on April 10, 2025. The festival honors his teachings of non-violence (Ahimsa), truth (Satya), compassion, and ...

Sanofi India Limited announced on Wednesday that its Managing Director, Rodolfo Hrosz, will step down from his role effective April 30, 2025, to take up another position within the Sanofi group, the ...

Credit: Kateryna Kon / Shutterstock. At the American Academy of Neurology (AAN) 2025 Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in ...

Try Now>> See the top stocks recommended by analysts >> Read More on SNY: Disclaimer & Disclosure Report an Issue Sanofi NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

On 7 April, Dalal Street saw a dramatic downturn as widespread panic-selling caused a steep decline in market valuations. A staggering ₹16 lakh crore in market value was wiped out—the most ...

Arab Finance: Egypt signed four cooperation agreements with Sanofi and the Gustave Roussy Institute to enhance healthcare services and strengthen Egyptian-French collaboration in the health sector, as ...

Supported by Sanofi. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank the trial participants and their families and caregivers ...

Mumbai: Sanofi Consumer Healthcare India Limited has announced the upcoming departure of two of its senior leaders. Maithilee Mistry, Whole-time Director and Chief Financial Officer, has resigned to ...

South Ko­re­an biotech ABL Bio has lined up an­oth­er plat­form li­cense agree­ment with a Eu­ro­pean phar­ma gi­ant in the area of neu­rode­gen­er­a­tive dis­eases.